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Abstract The new functional role of activated protein C (APC)
in the regulation of tissue factor (TF) expression was investigated
using the cultured human monoblastic leukemia U937 cell line. A
flow cytofluorometric analysis demonstrated that treatment with
APC resulted in time- and dose-dependent decrease in TF
expression in unstimulated and phorbol ester-stimulated cells.
The effect was antagonized by the monoclonal antibody (mAb) to
endothelial protein C/APC receptor (EPCR), 252, which
strongly inhibited the interaction between APC and EPCR. In
contrast, mAbs 49 and 379, which bind to EPCR without
blocking APC binding, had no or only a modest effect. It is
concluded that culturing U937 cells in the presence of APC
caused down-regulation of TF expression through the EPCR-
dependent mechanism, independent of whether induction was
triggered by phorbol ester. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Tissue factor (TF) is the integral membrane protein that
may initiate the blood clotting cascade in hemostasis and
many thrombotic disorders [1,2], unstable angina [3], athero-
sclerotic plaque formation [4], and pre-eclampsia [5]. There is
evidence that local ¢brin deposition mediated by the expres-
sion of the procoagulant TF is one of the initial steps in pre-
eclampsia-mediated vasculopathy [5,6]. It has also been re-
ported that macrophages are activated in patients with pre-
eclampsia [7], and that monocytes and macrophages can be
induced to express procoagulant activity or cell surface TF by
several in£ammatory mediators [8]. It is therefore important
to understand how TF expression is controlled in activated
monocytes or macrophages.
Activation of protein C to its active serine protease, acti-
vated protein C (APC), initiates a series of events that play a
key role in the regulation of blood coagulation [9^14]. APC
functions as an anticoagulant in plasma by inactivating FVa
and FVIIIa on membrane surfaces, a process that is potenti-
ated by the plasma vitamin K-dependent factor, protein S
[15,16]. At present, APC is considered to be one of the anti-
coagulant agents of choice for pre-eclampsia. The introduc-
tion of APC has led to an improvement in severe pre-eclamp-
sia-induced DIC. However, despite its successful use in
patients with pre-eclampsia, the precise mechanism of the in-
hibitory action of APC is still poorly understood.
It has been established that endothelial cells play a critical
role in the PC pathway in that they express two of the known
receptors responsible for e⁄cient PC activation: thrombomo-
dulin [9,17] and the endothelial protein C receptor (EPCR)
[18^22]. EPCR is a recently identi¢ed receptor with signi¢cant
homology to the CD1/MHC class I family. EPCR binds both
PC and APC with similar a⁄nity (Kd =V30 nM), facilitates
PC activation by presenting the PC substrate to the throm-
bin^thrombomodulin complex.
In attempting to understand the mechanism through which
APC regulates procoagulant activity, we have carried out ex-
periments to test the e¡ects of APC on the TF expression of
cells of monocyte/macrophage lineage. In the present study,
we investigated whether APC in£uences the TF expression in
unstimulated and phorbol ester-stimulated U937 cells, and
whether its e¡ect is conducted through the EPCR-dependent
mechanism.
2. Materials and methods
2.1. Production of monoclonal antibodies (mAbs) raised against EPCR
mAbs raised against EPCR were prepared as described previously
[23]. The antibodies were designated 49, 252 and 379. These mAbs
were used for £ow cyto£uorometric analyses. A puri¢ed preparation
of each antibody was biotinylated according to the method of Gues-
don et al. [24], using N-hydroxysucciminidyl biotinamidocaproate
(Sigma Chemical Co., St. Louis, MO, USA) using the manufacturer’s
suggested procedures.
2.2. Cells and culture conditions
Human promyeloid monoblastic leukemia cell line, U937, was
grown and cultured as previously described [25]. U937 cells were
grown at a density of 3^5U105 cells/ml in RPMI 1640 supplemented
with 10% fetal calf serum (Life Technologies, Grand Island, NY,
USA), 100 U/ml penicillin and 100 Wg/ml streptomycin in an atmos-
phere of 5% CO2, 95% air. Di¡erentiated (stimulated) U937 cells were
obtained by incubation in the above medium containing 1 WM phor-
bol-12-myristate-13-acetate 4-O-methyl ester (PMA; Sigma). A 2 day
incubation period resulted in approximately s 85% adherent cells.
Adherent cells were detached by pipetting, harvested by centrifuga-
tion, washed with binding bu¡er (see below) and used for the binding
experiments.
2.3. Preparation of £uorescein isothiocyanate (FITC)-labeled APC
APC puri¢ed from human serum was a generous gift of Kaketsuk-
en (The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Ja-
pan). 0.5 mg of the £uorescent dye FITC (Sigma) in 0.5 ml dimethyl
sulfoxide was added to the puri¢ed APC (5 mg/5 ml 0.1 M carbonate
bu¡er, pH 9.2) and incubated for 3 h at 23‡C. Resulting FITC-labeled
APC was puri¢ed by Sephadex G-25 gel ¢ltration (PD-10 column;
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Pharmacia, Uppsala, Sweden). Incorporation of FITC into APC was
veri¢ed by exposing sodium dodecyl sulfate^polyacrylamide gels to
long wave ultraviolet light.
2.4. Binding of FITC-labeled APC to the EPCR on U937 cells
Single cell-associated £uorescence was quanti¢ed by £ow cyto£uo-
rometry with the EPICS XL £ow cyto£uorometer (Beckman-Coulter,
Co., Fullerton, CA, USA; low-power argon laser excitation at 488
nm). Binding of FITC-labeled APC to unstimulated and PMA-stimu-
lated U937 cells was performed essentially as described earlier [25,26].
The cell pellet was washed twice and resuspended in 1 ml phosphate-
bu¡ered saline, 0.1% bovine serum albumin, 2 mM CaCl2, pH 7.3
(binding bu¡er) containing 0^20 Wg/ml FITC-labeled APC (1^2 h at
4‡C). After incubation, the cells were centrifuged, resuspended in 1 ml
binding bu¡er, and then cell-associated £uorescence was quanti¢ed by
£ow cyto£uorometry. Non-speci¢c binding of FITC-labeled APC to
U937 cells was determined in the presence of excess of parent APC.
The capacity of mAbs against EPCR (49, 252 and 379) to block
binding of FITC-labeled APC to EPCR on U937 cells was tested as
follows: inhibition of FITC-labeled APC binding by anti-EPCR
mAbs was measured by preincubation of the cells (106 cells/ml) with
anti-EPCR mAbs or non-immune IgG (50 Wg/ml) in binding bu¡er for
1 h at 4‡C. Subsequently, a saturating concentration of FITC-labeled
APC (10 Wg/ml, ¢nal concentration) was added and incubated for 1 h
at 4‡C. Bound ligand was quanti¢ed by £ow cyto£uorometry. Be-
tween each incubation step, the cells were washed three times with
binding bu¡er.
In addition, the capacity of EPCR-speci¢c mAbs to detect cell sur-
face EPCR was tested. Washed cells were incubated in binding bu¡er
with and without excess of unlabeled APC (20 Wg/ml) to saturate the
EPCR (2 h, 4‡C). Cells were subsequently washed to remove unbound
APC and then biotinylated mAbs against EPCR (49, 252 and 379)
were added (5 Wg/106 cells/ml; 1 h, 4‡C). After another washing, 3 Wl
of FITC-labeled avidin (Dako, Copenhagen, Denmark) was added (1
h, 4‡C). Cells were washed to remove excess free £uorescent probe
and then assessed for cell-bound £uorescence by £ow cyto£uorometry.
2.5. E¡ect of APC on TF expression on plasma membrane of U937
cells
Cell-associated TF expression was determined by £ow cyto£uorom-
etry. Unstimulated and PMA-stimulated U937 cells were incubated
with APC (0^20 Wg/ml) or vehicle for 1, 3, 6, 12 and 24 h in RPMI
1640 containing binding bu¡er. In a parallel experiment, U937 cells
were coincubated with the mAbs against EPCR in the presence of
APC or vehicle as indicated above. MAbs were used at a ¢nal con-
centration of 50 Wg/ml. Rat preimmune IgG was diluted at the same
concentration and used as a control. Cells were subsequently washed
and then mAb against human TF (American Diagnostica, Greenwich,
CT, USA) was added (5 Wg/106 cells/ml; 1 h, 4‡C). After another
washing, 3 Wl of FITC anti-mouse IgG (Dako) was added (1 h,
4‡C). Cells were washed to remove excess free £uorescent probe and
then assessed for cell-bound £uorescence by £ow cyto£uorometry. All
experiments were performed using at least two di¡erent cell prepara-
tions. The binding data presented are the mean of duplicate determi-
nations in one representative experiment of two or three independent
studies.
Each reagent is tested for endotoxin contamination. The levels of
endotoxin have been below the detection limit of 30 pg/ml.
3. Results
3.1. Assessment of binding of APC to its speci¢c binding sites
on living U937 cells by £ow cyto£uorometry
Binding of FITC-labeled APC to its receptor (EPCR) on
unstimulated and PMA-stimulated U937 cells was quanti¢ed
by £ow cyto£uorometry (Fig. 1). Binding of FITC^APC to
EPCR on U937 cells depends on the concentration of FITC^
APC and time of incubation. Apparent saturation of binding
was achieved at approximately 10 Wg/ml FITC^APC for both
unstimulated and PMA-stimulated U937 cells for 1 h at 4‡C.
Binding was higher with PMA-stimulated cells. The £uores-
cence intensity obtained within 1 h at 4‡C remained un-
changed up to 2 h of incubation. Binding of FITC^APC is
inhibited by excess of parent APC. 50% displacement is ob-
tained at a molar ratio of 1:2 for APC and FITC^APC (data
not shown). Binding of FITC^APC to unstimulated and
stimulated cells was almost completely inhibited by a 20-fold
molar excess of unlabeled APC.
3.2. Inhibition of binding of FITC-labeled APC by mAbs
directed to various epitopes of EPCR
Unstimulated and PMA-stimulated U937 cells were prein-
cubated with 50 Wg/ml of mAbs against EPCR (49, 252 or
379) or non-immune IgG and then binding of FITC^APC
(10 Wg/ml) to U937 cells quanti¢ed by £ow cyto£uorometry.
All three antibodies bound essentially equivalently to U937
Fig. 1. The binding of increasing concentrations of FITC-labeled APC by unstimulated and PMA-stimulated U937 cells was determined by
£ow cyto£uorometric analysis. A: The PMA-stimulated cells were incubated with FITC-labeled APC at increasing doses in the presence or ab-
sence of an excess amount of unlabeled APC. B: The speci¢c binding of FITC-labeled APC by unstimulated (E) and PMA-stimulated (gray)
U937 cells. The representative results of two independent experiments are shown.
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cells (data not shown). MAb inhibition of FITC^APC binding
to the EPCR on U937 cells is shown in Fig. 2. Even at high
concentrations (50 Wg/ml) of mAb 49, no inhibition was ob-
served. MAb 379 showed only partial inhibition of FITC^
APC binding. Preincubation of the mAb 252 to the cells,
however, considerably reduced subsequent binding of FITC^
APC. More than 90% inhibition was seen when the mAb 252
was applied to the cells at a concentration of 50 Wg/ml. These
results indicate that mAb 252 speci¢cally reacts with peptide
sequence representing the ligand binding epitope of EPCR.
In a parallel experiment, U937 cells were preincubated with
APC (20 Wg/ml) and then binding of mAbs against EPCR to
U937 cells quanti¢ed by £ow cyto£uorometry (Fig. 3). Prein-
cubation of APC to the cells considerably reduced subsequent
binding of mAb 252. Little inhibition of binding of mAbs 49
and 379 (about 6 20%) was seen by preincubation of APC.
Treatment with varying concentrations of APC resulted in
dose-dependent decrease in mAb 252 binding in unstimulated
and phorbol ester-stimulated cells (data not shown). These
results also support the hypothesis that mAb 252 reacts with
peptide sequence representing the APC binding epitope of
EPCR. Thus, mAb 252 blocks APC binding to cellular
EPCR by steric hindrance, but other antibodies bind to
EPCR without blocking APC binding.
It has been established that not only EPCR but also throm-
Fig. 2. The binding of FITC-labeled APC (10 Wg/ml) by PMA-
stimulated U937 cells was determined by £ow cyto£uorometric anal-
ysis after preincubation in the absence or presence of anti-EPCR
antibodies (49, 252 and 379; 50 Wg/ml), non-immune IgG (N-IgG;
50 Wg/ml) or APC (50 Wg/ml). Characterization was performed in
unstimulated U937 cells, demonstrating almost the same inhibition.
The representative results of two independent experiments are
shown.
Fig. 3. Biotinylated anti-EPCR antibody binding to PMA-stimulated
U937 cells in the absence or presence of APC was assessed by £ow
cyto£uorometry. The cells were incubated with 5 Wg/ml of biotinyl-
ated mAb after preincubation in the presence of unlabeled APC
(20 Wg/ml). Biotin mAb binding was detected by incubation with
FITC-labeled streptavidin. This experiment is representative of two
similar observations.
Fig. 4. E¡ect of APC on the TF expression in PMA-stimulated U937 cells. A: Dose^response study: TF expression was measured on the cell
surface after incubating the PMA-stimulated U937 cells with increasing doses of APC (0^20 Wg/ml) for 6 h by £ow cyto£uorometry. B: Time-
course study: TF expression was measured on the cell surface after incubating the cells with APC (10 Wg/ml) for the indicated times by £ow
cyto£uorometry. The representative results of two independent experiments are shown. Characterization was performed in unstimulated U937
cells, demonstrating almost the same inhibition.
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bomodulin are expressed on the cell surface of U937 cells by
£ow cyto£uorometry (unpublished data; Tsuneyoshi and Fu-
kudome, 1999). MAb 252 does not react with thrombomodu-
lin by solid-phase binding assay (data not shown). When con-
sidered together, these data suggest that it is unlikely that cell-
associated thrombomodulin is responsible for APC binding
sites.
3.3. E¡ect of APC on TF expression on U937 cell surface
Dose^response and time-course studies: to better character-
ize the properties of the APC action of U937 cells, we per-
formed both dose^response and time-course studies on APC-
mediated regulation of TF expression in unstimulated and
PMA-stimulated cells. When the control cells were stimulated
by PMA, they demonstrated a 1.5-fold increase in TF expres-
sion (data not shown). As shown in Fig. 4A, TF expression
was dose-dependently down-regulated when the stimulated
cells were treated with APC for 6 h, and the e¡ective concen-
tration of APC necessary to inhibit TF expression by 50%
(ID50) was V5 Wg/ml for unstimulated and PMA-stimulated
cells. The presence of 20 Wg/ml APC in the conditioned me-
dium of unstimulated and stimulated cells reduced the basal
expression of TF to V45% of that in the control cells 6 h
after the treatment. Thus, APC signi¢cantly reduced the basal
TF expression, independent of whether stimulation was trig-
gered by PMA.
Fig. 4B illustrates the time course of APC inhibition of TF
expression, using an APC concentration of 20 Wg/ml for the
stimulated cells. Signi¢cant down-regulation of TF expression
on the surface of stimulated cells was observed after 3 h and
reached a nadir after 6 h. The cells cultured for 12 h showed a
higher level of TF expression than those cultured for 6 h. In a
parallel experiment, down-regulation of the TF expression on
the surface of unstimulated cells was also signi¢cant by 3 h
and maximal after 6 h. Levels of TF expression then returned
to control levels after 12 h (data not shown).
3.4. E¡ect of mAbs against EPCR on APC-dependent
down-regulation of TF expression
It is likely that the e¡ect of APC on TF expression may
function via EPCR on U937 cells. MAb 252 inhibits the bind-
ing of APC to cellular EPCR, whereas mAbs 49 and 379 do
not. Therefore, in order to determine whether binding of APC
to EPCR is involved in the down-regulation of TF in U937
cells, we conducted experiments in the presence of each mAb
against EPCR. Unlike cells treated with APC alone, when
PMA-stimulated cells (Fig. 5) were treated with a combina-
tion of mAb 252 (50 Wg/ml) and APC (20 Wg/ml), they ex-
pressed TF at levels that were essentially the same as cells
treated without APC. Thus, mAb 252 completely abrogated
the e¡ect of APC on TF levels in U937 cells. On the other
hand, mAbs 49 and 379 failed to block the ability of APC to
down-regulate TF expression. Characterization was also per-
formed in unstimulated U937 cells, in which almost the same
results were obtained (data not shown). These results indicate
that APC is required to bind to EPCR in order to down-
regulate TF expression in U937 cells.
4. Discussion
APC has been considered to decrease procoagulant activity
directly via inactivation of FVa/VIIIa [9,10,27]. Furthermore,
we have previously reported that APC enhances the cell-asso-
ciated ¢brinolytic activity [28]. Thus, other bene¢cial anti-
thrombotic e¡ects ascribed to APC include enhanced pro¢bri-
nolytic activity via an increase in plasminogen activator activ-
ity.
TF is known to be transiently inducible in vascular endo-
thelial cells and monocytes/macrophages by a variety of stim-
uli (LPS, phorbol ester and cytokines including IL-1L, TNF-K
and IFN-Q) [29^31]. Recently, it was shown by Murakami et
al. [32] that induction of cytokines in vascular endothelial cells
or macrophage activated by LPS can be down-regulated by
APC. These ¢ndings led us to investigate the e¡ect of APC on
monocytes/macrophage TF expression. To study the mecha-
nisms through which APC induces an anti-thrombotic e¡ect,
it is often necessary to place the target cells of interest in
culture or to use cancer cells instead of normal cells. Here
we have used a commercially available human monoblastic
promyeloid leukemia cell line U937 to determine whether
APC a¡ects the expression of cell-associated TF in vitro, since
we and others [23] found that these cells have cell-associated
binding sites for APC.
In the present study, we found that there is a speci¢c and
functional binding site for APC (EPCR) located on the plas-
ma membrane of the U937 cells. Treatment with APC resulted
in dose-dependent decrease in TF expression in unstimulated
and phorbol ester-stimulated cells, saturable with an EC50 of
V5 Wg/ml for APC. Treatment of the cells with APC resulted
in a time-dependent inhibition of TF expression that was sig-
ni¢cant by 3 h and maximal after 6 h. Levels of TF expression
then returned to control levels after 12 h. Therefore, we con-
clude that APC induced a consistent, statistically signi¢cant
decrease in TF expression in a dose- and time-dependent fash-
ion, the decrease was relatively slow and the e¡ect was tran-
sient, and that APC signi¢cantly down-regulated U937 TF
expression, independent of whether induction was triggered
by PMA. Furthermore, we have investigated whether APC
in£uences the expression of TF via direct binding of APC
Fig. 5. Monoclonal anti-EPCR antibody abrogates APC-dependent
down-regulation of TF expression. TF antigen expression on PMA-
stimulated U937 cells was assessed by £ow cyto£uorometry. MAb
252 (50 Wg/ml) almost completely reversed the suppressive e¡ects of
APC in terms of TF expression, while mAbs 379 and 49 (data not
shown) were not e⁄cacious in this regard. The representative results
of two independent experiments are shown.
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to EPCR on the U937 cells. We have previously developed a
protocol to generate mAbs. By this approach, domain-speci¢c
antibodies were produced [23]. The present study showed that
mAb 252 did not react with cellular EPCR occupied by APC.
Preincubation of cellular EPCR with mAb 252 strongly inhib-
ited interaction of APC with EPCR. Therefore, mAb 252
blocks APC binding to the EPCR, while mAbs 49 and 379
reacted with cellular EPCR without blocking APC binding.
This feature points to that these mAbs recognize conforma-
tion-dependent and domain-speci¢c epitopes. Thus, the region
recognized by mAb 252 seems to be critical for binding of
APC. Our experiments using mAbs to EPCR strongly indi-
cated that its inhibitory e¡ect on TF expression appears to be
conducted through the EPCR mechanism, since a monoclonal
anti-EPCR antibody 252 e⁄ciently blocked the APC-depen-
dent down-regulation of TF expression.
Inhibition of TF expression by APC was observed at con-
centrations neither a¡ecting total protein synthesis nor being
directly cytotoxic to the cells (data not shown). To our knowl-
edge, this is the ¢rst report showing that APC directly de-
creases U937 cell TF expression through the EPCR mecha-
nism. Our present results support the hypothesis that APC-
induced down-regulation of TF expression may contribute to
its successful use in anti-preeclamptic medicine.
It is possible that certain cytokines are responsible for the
APC’s e¡ect shown here. This statement is based on the
events reported for cytokine-induced up-regulation of TF ex-
pression [31,33] and APC-mediated down-regulation of cyto-
kine release [32]. We thus speculate that APC may block TF
expression by down-regulating cytokine release. We have been
examining whether neutralizing antibodies to several types of
cytokine modulate TF expression by APC. Further studies
will be required to determine whether APC reduces the tran-
scription of the TF gene or whether APC causes down-regu-
lation of TF expression via reducing its half-life or enhancing
internalization and degradation.
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